NYSE:BSX Boston Scientific (BSX) Stock Price, News & Analysis $42.16 -0.25 (-0.58%) As of 02:25 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Boston Scientific Stock (NYSE:BSX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Boston Scientific alerts:Sign Up Key Stats Today's Range$42.21▼$42.7550-Day Range$42.40▼$52.0252-Week Range$41.94▼$105.65Volume6.06 million shsAverage Volume18.69 million shsMarket Capitalization$61.09 billionP/E Ratio17.07Dividend YieldN/APrice Target$67.88Consensus RatingModerate Buy Company Overview Boston Scientific Corporation is a global medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of medical conditions. Its products are designed to support minimally invasive procedures across areas including cardiovascular care, endoscopy, urology, pelvic health and neuromodulation. The company’s portfolio includes devices for interventional cardiology and peripheral interventions, electrophysiology and cardiac rhythm management, gastrointestinal and pulmonary procedures, kidney stone and prostate treatments, urinary and pelvic health, and chronic pain management. Boston Scientific also provides technologies used in the diagnosis and treatment of structural heart conditions and other complex diseases. Founded in 1979, Boston Scientific is headquartered in Marlborough, Massachusetts, and serves hospitals, healthcare professionals and patients in markets around the world. The company operates through a global network of research, manufacturing and commercial operations. Michael F. Mahoney serves as chairman and chief executive officer.AI Generated. May Contain Errors. Read More Boston Scientific Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks96th Percentile Overall ScoreBSX MarketRank™: Boston Scientific scored higher than 96% of companies evaluated by MarketBeat, and ranked 14th out of 885 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingBoston Scientific has received a consensus rating of Moderate Buy. The company's average rating score is 2.70, and is based on no strong buy ratings, 23 buy ratings, 5 hold ratings, and 2 sell ratings.Upside PotentialBoston Scientific has a consensus price target of $67.88, representing about 60.0% upside from its current price of $42.42.Amount of Analyst CoverageBoston Scientific has been the subject of 16 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Boston Scientific's stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth3.38% Earnings GrowthEarnings for Boston Scientific are expected to grow by 3.38% in the coming year, from $3.25 to $3.36 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Boston Scientific is 17.18, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.69.Price to Earnings Ratio vs. SectorThe P/E ratio of Boston Scientific is 17.18, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.29.Price to Earnings Growth RatioBoston Scientific has a PEG Ratio of 1.02. PEG Ratios around 1 indicate that a company is correctly valued.Price to Book Value per Share RatioBoston Scientific has a P/B Ratio of 2.57. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Boston Scientific's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.22% of the float of Boston Scientific has been sold short.Short Interest Ratio / Days to CoverBoston Scientific has a short interest ratio ("days to cover") of 2.35, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Boston Scientific has recently decreased by 3.46%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBoston Scientific does not currently pay a dividend.Dividend GrowthBoston Scientific does not have a long track record of dividend growth. News and Social Media1.3 / 5News Sentiment0.01 News SentimentBoston Scientific has a news sentiment score of 0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.41 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Boston Scientific this week, compared to 8 articles on an average week.Search InterestOnly 83 people have searched for BSX on MarketBeat in the last 30 days. This is a decrease of -1% compared to the previous 30 days.MarketBeat FollowsOnly 20 people have added Boston Scientific to their MarketBeat watchlist in the last 30 days. This is a decrease of -23% compared to the previous 30 days. Company Ownership4.3 / 5Insider TradingAcquiring Shares Cluster Insider Buying3 insiders have purchased shares of Boston Scientific in the last three months. Multiple insiders buying is a strong bullish signal.Net Insider BuyingOver the last three months, insiders have purchased a net $9,385,210.00 in company stock, which represents 0.0153% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Boston Scientific insiders have bought more of their company's stock than they have sold. Specifically, they have bought $9,385,210.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders0.34% of the stock of Boston Scientific is held by insiders.Percentage Held by Institutions89.07% of the stock of Boston Scientific is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Boston Scientific's insider trading history. Receive BSX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Boston Scientific and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BSX Stock News HeadlinesElutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029October 1, 2026 | globenewswire.comBoston Scientific Corporation (NYSE:BSX) Stock Has Consensus Price Target of $70.19September 30, 2026 | americanbankingnews.comElon Warns "America Will Go Bankrupt". Trump's Plan Inside.National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt without major changes. As former head of the Department of Government Efficiency under President Trump, Musk saw firsthand how looming spending cuts could rattle markets and squeeze 401ks, IRAs, and TSPs. A preserved IRS provision may help everyday investors shield their retirement savings before the next wave of volatility hits.October 6 at 1:00 AM | American Hartford Gold (Ad)Boston Scientific: Market Pessimism Has Pushed The Stock Into Undervalued TerritorySeptember 29, 2026 | seekingalpha.comHow Big Could BSX Stock's Next Fall Be?September 28, 2026 | finance.yahoo.comCould Boston Scientific’s $300 Million Cyber Hit Be Mostly a 2026 Problem?September 28, 2026 | insidermonkey.comBoston Scientific (BSX) Faces A Recall, Is The 28% Undervaluation Still Compelling?September 28, 2026 | finance.yahoo.comFDA Flags Boston Scientific Catheter RecallSeptember 28, 2026 | benzinga.comSee More Headlines BSX Stock Analysis - Frequently Asked Questions How have BSX shares performed this year? Boston Scientific's stock was trading at $95.29 at the beginning of the year. Since then, BSX stock has decreased by 55.5% and is now trading at $42.4220. How were Boston Scientific's earnings last quarter? Boston Scientific Corporation (NYSE:BSX) posted its quarterly earnings data on Wednesday, July, 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, beating analysts' consensus estimates of $0.83 by $0.03. The firm's revenue for the quarter was up 7.5% on a year-over-year basis. Read the conference call transcript. Is Boston Scientific buying back stock? Boston Scientific's board approved a stock buyback program on Monday, May 18th 2026, which authorizes the company to repurchase $5,000,000,000 in shares, according to EventVestor. This means that the company could purchase up to 6.4% of its shares through open market purchases. Shares buyback programs are often a sign that the company's board of directors believes its stock is undervalued. Does Boston Scientific have any subsidiaries? Boston Scientific subsidiaries include VertiFlex, BTG, Augmenix, Veniti, Claret Medical, Cryterion Medical, nVision Medical, and others. Who are Boston Scientific's major shareholders? Boston Scientific's top institutional shareholders include Neville Rodie & Shaw Inc., Eastern Bank, MassMutual Private Wealth & Trust FSB and Central Pacific Bank Trust Division. Insiders that own company stock include Michael F Mahoney, Daniel J Brennan, Joseph Michael Fitzgerald, Vance R Brown, Eric Francis Yves Thepaut, Edward J Ludwig, Edward J Ludwig, Wendy Carruthers, Jeffrey B Mirviss, Ellen M Zane, Arthur C Butcher, John Bradley Sorenson, David C Habiger, Yoshiaki Fujimori, Cheryl Pegus and Charles J Dockendorff. View institutional ownership trends. How do I buy shares of Boston Scientific? Shares of BSX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Boston Scientific own? Based on aggregate information from My MarketBeat watchlists, some other companies that Boston Scientific investors own include BlackRock (BLK), Broadcom (AVGO), ServiceNow (NOW), UnitedHealth Group (UNH), The Goldman Sachs Group (GS), NVIDIA (NVDA) and Illinois Tool Works (ITW). Company Calendar Last Earnings7/29/2026Today10/06/2026Next Earnings (Estimated)10/28/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1d) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 BSX's financial health is in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolNYSE:BSX CIK885725 Webwww.bostonscientific.com Phone(508) 683-4000Fax508-683-5675Employees59,000Year Founded1979Price Target and Rating Average Price Target for Boston Scientific$67.88 High Price Target$118.00 Low Price Target$48.00 Potential Upside/Downside+61.0%Consensus RatingModerate Buy Rating Score (0-4)2.70 Research Coverage30 Analysts Profitability EPS (Trailing Twelve Months)$2.47 Trailing P/E Ratio17.07 Forward P/E Ratio12.97 P/E Growth1.02Net Income$2.90 billion Net Margins17.50% Pretax Margin18.39% Return on Equity19.28% Return on Assets10.89% Debt Debt-to-Equity Ratio0.43 Current Ratio1.24 Quick Ratio0.74 Sales & Book Value Annual Sales$20.07 billion Price / Sales3.04 Cash Flow$3.99 per share Price / Cash Flow10.56 Book Value$16.49 per share Price / Book2.56Miscellaneous Outstanding Shares1,449,230,000Free Float1,444,303,000Market Cap$61.09 billion OptionableOptionable Beta0.58 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NYSE:BSX) was last updated on 10/6/2026 by MarketBeat.com Staff. From Our PartnersNvidia’s record quarter could send this new type of AI soaringNvidia just posted 96.2 billion in revenue for a single quarter, more than Coca-Cola generates in an entire ye...Brownstone Research | SponsoredDOJ Admits It In Court—Your Cash Can Be Seized Without WarningThe Department of Justice recently argued in court that cash may not be legally your property - raising concer...Priority Gold | SponsoredElon Warns "America Will Go Bankrupt". Trump's Plan Inside.National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt with...American Hartford Gold | SponsoredA weekly dividend fund holding Nvidia and PalantirCrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...Investors Alley | SponsoredThis smart glasses tech is bringing the screen to your eyesGlobal AI smart-glasses shipments surged 263% in the first half of 2026, and Citi projects the market could re...The Tomorrow Investor | SponsoredThe case for $20,000 gold before year endPresident Trump reposted a warning from precious metals expert Jim Rickards, tying the November midterms and A...Stansberry Research | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Boston Scientific Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Boston Scientific With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
